Prostate cancer remains the most common cancer in men. Qualitative or semi-quantitative immunochromatographic measurements of prostate specific antigen (PSA) have been shown to be simple, noninvasive and feasible. The aim of this study was to evaluate an optimized gold immunochromatographic strip device for the detection of PSA, in which the results can be analysed using a Chromogenic Rapid PYLARIFY is used along with positron emission tomography (PET) imaging for men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum levels of prostate-specific antigen (PSA) level. PYLARIFY Injection is designed to detect prostate-specific membrane 1. Introduction. Recently released clinical practice guidelines (CPGs) no longer recommend decision thresholds of prostate-specific antigen (PSA) for the early detection of prostate cancer (PCa) to rule in patients for prostate biopsy referral [1,2,3].Rather the expert panels have endorsed the stratification of PCa risk according to individual PSA values and age, aiming to offer biopsy to Introduction. Advanced T stage, high Gleason grades and high serum levels of prostate-specific antigen (PSA) are associated with bone metastases in men with prostate cancer [1,2].Based on results from some small, single centre studies published in the beginning of the 1990s, PSA levels above 100 ng/mL have been used as a proxy for metastatic prostate cancer [3-5]. With the introduction of prostate-specific antigen (PSA) testing, the number of PCa diagnoses has increased, but the rate of dying from PCa has decreased [6-10]. Although a routine test, PSA screening has garnered a lot of criticism over the years due to the possibility of over detection, which leads to over treatment [11-14]. Prostate-Specific Antigen (PSA) is a first-line recommended serum biomarker used for prostate cancer (PCa) screening. However, this test has critical limitations in specificity within the gray .

sensitivity of psa test for prostate cancer